Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

by Iversen, Peter , Mainwaring, Paul , Miller, Kurt , Perabo, Frank , Mansbach, Harry , Tombal, Bertrand , Evans, Christopher P , Chowdhury, Simon , Kim, Choung-Soo , Carles, Joan , Taplin, Mary-Ellen , de Bono, Johann S , Phung, De , Joshua, Anthony M , Venner, Peter M , Fizazi, Karim , Scher, Howard I , Saad, Fred , Davis, Ian D , Bhattacharya, Suman , Armstrong, Andrew J , Loriot, Yohann , Rathkopf, Dana E , Sternberg, Cora N , Kimura, Go , Higano, Celestia S , Beer, Tomasz M , Noonberg, Sarah B

in Adenocarcinoma - drug therapy / Adenocarcinoma - mortality / Adenocarcinoma - secondary / Administration, Oral / Androgen Receptor Antagonists - adverse effects / Androgen Receptor Antagonists - therapeutic use / Androgen receptors / Antineoplastic Agents, Hormonal - adverse effects / Antineoplastic Agents, Hormonal - therapeutic use / Benzamides / Biological and medical sciences / Cancer / Cancer and Oncology / Cancer och onkologi / Castration / Chemotherapy / Clinical Medicine / Cytotoxicity / Disease Progression / Double-Blind Method / Fatigue / General aspects / Gynecology. Andrology. Obstetrics / Humans / Inhibitor drugs / Klinisk medicin / Life Sciences / Male / Male genital diseases / Medical and Health Sciences / Medical sciences / Medicin och hälsovetenskap / Metastases / Metastasis / Neoplasm Metastasis - diagnostic imaging / Nephrology. Urinary tract diseases / Nitriles / Patients / Phenylthiohydantoin - adverse effects / Phenylthiohydantoin - analogs & derivatives / Phenylthiohydantoin - therapeutic use / Prostate cancer / Prostate-specific antigen / Prostatic Neoplasms - drug therapy / Prostatic Neoplasms - mortality / Prostatic Neoplasms - pathology / Radiography / Receptors, Androgen / Survival / Survival Analysis / Tumors / Tumors of the urinary system / Urinary tract. Prostate gland

2014

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

2014

Confirm

Do you wish to request the book?

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

2014

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Iversen, Peter,

Mainwaring, Paul,

Miller, Kurt,

Perabo, Frank,

Mansbach, Harry,

Tombal, Bertrand,

Evans, Christopher P,

Chowdhury, Simon,

Kim, Choung-Soo,

Carles, Joan,

Taplin, Mary-Ellen,

de Bono, Johann S,

Phung, De,

Joshua, Anthony M,

Venner, Peter M,

Fizazi, Karim,

Scher, Howard I,

Saad, Fred,

Davis, Ian D,

Bhattacharya, Suman,

Armstrong, Andrew J,

Loriot, Yohann,

Rathkopf, Dana E,

Sternberg, Cora N,

Kimura, Go,

Higano, Celestia S,

Beer, Tomasz M,

Noonberg, Sarah B

2014

Overview

In this study, the androgen-receptor inhibitor enzalutamide improved progression-free and overall survival in men with castration-resistant metastatic prostate cancer who had not received chemotherapy. Prostate cancer is the most commonly diagnosed cancer and the sixth leading cause of cancer-related death among men worldwide. 1 Strategies to block androgen-receptor signaling have formed the backbone of prostate-cancer therapy since the first description of the hormonal dependence of this cancer in 1941. 2 Advances in endocrine therapies have improved survival in men with high-risk locoregional prostate cancer. 3 , 4 However, new hormonal agents have been shown to extend survival in men with metastatic castration-resistant disease. 5 – 9 In most patients who are treated for advanced recurrent prostate cancer with androgen-deprivation therapy (comprising a luteinizing hormone–releasing hormone [LHRH] analogue or orchiectomy with . . .

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenocarcinoma - drug therapy

/ Adenocarcinoma - mortality

/ Adenocarcinoma - secondary

/ Administration, Oral

/ Androgen Receptor Antagonists - adverse effects

/ Androgen Receptor Antagonists - therapeutic use

/ Androgen receptors